These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10737478)

  • 21. Testing for urinary hyaluronate improves detection and grading of transitional cell carcinoma.
    Passerotti CC; Srougi M; Bomfim AC; Martins JR; Leite KR; Dos Reis ST; Sampaio LO; Ortiz V; Dietrich CP; Nader HB
    Urol Oncol; 2011; 29(6):710-5. PubMed ID: 19962919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
    Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH
    Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder.
    Jamshidian H; Kor K; Djalali M
    Urol J; 2008; 5(4):243-7. PubMed ID: 19101898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma.
    Hakenberg OW; Fuessel S; Richter K; Froehner M; Oehlschlaeger S; Rathert P; Meye A; Wirth MP
    Urology; 2004 Dec; 64(6):1121-6. PubMed ID: 15596183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Urine prothymosin-alpha as novel tumor marker for detection and follow-up of bladder cancer.
    Tzai TS; Tsai YS; Shiau AL; Wu CL; Shieh GS; Tsai HT
    Urology; 2006 Feb; 67(2):294-9. PubMed ID: 16461079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine.
    Halling KC; King W; Sokolova IA; Karnes RJ; Meyer RG; Powell EL; Sebo TJ; Cheville JC; Clayton AC; Krajnik KL; Ebert TA; Nelson RE; Burkhardt HM; Ramakumar S; Stewart CS; Pankratz VS; Lieber MM; Blute ML; Zincke H; Seelig SA; Jenkins RB; O'Kane DJ
    J Urol; 2002 May; 167(5):2001-6. PubMed ID: 11956427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
    Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF
    Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
    Giannopoulos A; Manousakas T; Gounari A; Constantinides C; Choremi-Papadopoulou H; Dimopoulos C
    J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnosis of bladder cancer by analysis of urinary fibronectin.
    Menéndez V; Fernández-Suárez A; Galán JA; Pérez M; García-López F
    Urology; 2005 Feb; 65(2):284-9. PubMed ID: 15708039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of two new urinary tumor markers: bladder tumor fibronectin and cytokeratin 18 for the diagnosis of bladder cancer.
    Sánchez-Carbayo M; Urrutia M; González de Buitrago JM; Navajo JA
    Clin Cancer Res; 2000 Sep; 6(9):3585-94. PubMed ID: 10999749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cellular fibronectin in patients with transitional cell carcinoma of the bladder.
    Hegele A; Heidenreich A; Varga Z; von Knobloch R; Olbert P; Kropf J; Hofmann R
    Urol Res; 2003 Feb; 30(6):363-6. PubMed ID: 12599015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The diagnosis and monitoring of transitional cell cancer of the urinary tract through nuclear matrix protein 22].
    Chen HQ; Han CZ; Du LL; Cui Y; Pang DZ; Jing JX; Zhao XW; Tian BG; Mi ZG
    Zhonghua Yu Fang Yi Xue Za Zhi; 2007 Jun; 41 Suppl():84-6. PubMed ID: 17767866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Usefulness of urinary nuclear matrix protein 22 (NMP22) as a marker for transitional cell carcinoma of the bladder.
    Menendez V; Filella X; Alcover JA; Molina R; Mallafre JM; Ballesta AM; Talbot-Wright R
    Anticancer Res; 2000; 20(2B):1169-72. PubMed ID: 10810416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-6/10 ratio as a prognostic marker of recurrence in patients with intermediate risk urothelial bladder carcinoma.
    Cai T; Mazzoli S; Meacci F; Tinacci G; Nesi G; Zini E; Bartoletti R
    J Urol; 2007 Nov; 178(5):1906-11;discussion 1911-2. PubMed ID: 17868727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CYFRA 21-1 quantity measurement in the urine of patients with carcinoma of the urinary bladder and tract.
    Schambeck CM; Stieber P; Schmeller N; Hofmann K; Pahl H; Fateh-Moghadam A
    Anticancer Res; 1997; 17(4B):3063-5. PubMed ID: 9329602
    [No Abstract]   [Full Text] [Related]  

  • 36. Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer.
    Moonen PM; Kiemeney LA; Witjes JA
    Eur Urol; 2005 Dec; 48(6):951-6; discussion 956. PubMed ID: 16257108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunocytochemical analysis of prostate stem cell antigen as adjunct marker for detection of urothelial transitional cell carcinoma in voided urine specimens.
    Cheng L; Reiter RE; Jin Y; Sharon H; Wieder J; Lane TF; Rao J
    J Urol; 2003 Jun; 169(6):2094-100. PubMed ID: 12771726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
    Kibar Y; Goktas S; Kilic S; Yaman H; Onguru O; Peker AF
    Ann Clin Lab Sci; 2006; 36(1):31-8. PubMed ID: 16501234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of Cyfra 21-1: a potential tumor marker for non-small cell lung carcinomas.
    Karnak D; Ulubay G; Kayacan O; Beder S; Ibis E; Oflaz G
    Lung; 2001; 179(1):57-65. PubMed ID: 11479694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urinary insulin-like growth factor 2 identifies the presence of urothelial carcinoma of the bladder.
    Watson JA; Burling K; Fitzpatrick P; Kay E; Kelly J; Fitzpatrick JM; Dervan PA; McCann A
    BJU Int; 2009 Mar; 103(5):694-7. PubMed ID: 19040529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.